|
WO2012104843A1
(en)
|
2011-02-06 |
2012-08-09 |
Yeda Research And Development Co.Ltd. At The Weizmann Institute Of Science |
Affinity maturated t cell receptors and use thereof
|
|
WO2016022400A1
(en)
*
|
2014-08-04 |
2016-02-11 |
Fred Hutchinson Cancer Research Center |
T cell immunotherapy specific for wt-1
|
|
GB201417803D0
(en)
|
2014-10-08 |
2014-11-19 |
Adaptimmune Ltd |
T cell receptors
|
|
EP3067366A1
(en)
|
2015-03-13 |
2016-09-14 |
Max-Delbrück-Centrum Für Molekulare Medizin |
Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
|
|
CN114195882A
(zh)
*
|
2015-10-01 |
2022-03-18 |
圣拉斐尔医院有限公司 |
Tcr及其用途
|
|
GB201520544D0
(en)
*
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
GB201520568D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd |
Peptides
|
|
GB201520550D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
EP3219800A1
(en)
|
2016-03-15 |
2017-09-20 |
Max-Delbrück-Centrum Für Molekulare Medizin |
A transposon-based transfection system for primary cells
|
|
CN106749620B
(zh)
*
|
2016-03-29 |
2020-09-25 |
广东香雪精准医疗技术有限公司 |
识别mage-a1抗原短肽的t细胞受体
|
|
ES2914648T3
(es)
*
|
2016-04-08 |
2022-06-15 |
Immunocore Ltd |
Receptores de células T
|
|
CN109641063B
(zh)
*
|
2016-04-20 |
2022-11-15 |
能源环境和技术研究中心O.A., M.P. |
用于增强pklr的基因表达的组合物和方法
|
|
CN106084042B
(zh)
*
|
2016-06-24 |
2020-01-14 |
安徽未名细胞治疗有限公司 |
一种全人源抗MAGEA1的全分子IgG抗体及其应用
|
|
CN110088128B
(zh)
*
|
2016-09-23 |
2023-11-28 |
来恩生物医药私人有限公司 |
Hbv抗原特异性结合分子及其片段
|
|
PT3551221T
(pt)
|
2016-12-08 |
2022-01-18 |
Immatics Biotechnologies Gmbh |
Novos recetores de células t e imunoterapia empregando os mesmos
|
|
DE102016123847B3
(de)
*
|
2016-12-08 |
2018-04-05 |
Immatics Biotechnologies Gmbh |
Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
|
|
CN108250289B
(zh)
*
|
2016-12-28 |
2021-10-08 |
香雪生命科学技术(广东)有限公司 |
源自于mage b6的肿瘤抗原短肽
|
|
JP7037577B2
(ja)
*
|
2017-03-15 |
2022-03-16 |
フレッド ハッチンソン キャンサー リサーチ センター |
高親和性mage-a1特異的tcr及びその使用
|
|
CN108929378B
(zh)
*
|
2017-05-22 |
2021-04-23 |
香雪生命科学技术(广东)有限公司 |
一种识别prame抗原的t细胞受体及编码该受体的核酸
|
|
CA3070468A1
(en)
|
2017-09-01 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
|
|
CN114026116A
(zh)
|
2019-02-20 |
2022-02-08 |
弗雷德哈钦森癌症研究中心 |
Ras新抗原特异性结合蛋白及其用途
|
|
US12448429B2
(en)
|
2019-03-06 |
2025-10-21 |
Dana-Farber Cancer Institute, Inc. |
T cell receptors specific to b-cell maturation antigen for treatment of cancer
|
|
TWI850360B
(zh)
*
|
2019-04-04 |
2024-08-01 |
德商梅迪基因免疫治療公司 |
黑色素瘤相關抗原1(magea1)特異性t細胞受體及其用途
|
|
MX2021015452A
(es)
|
2019-06-25 |
2022-02-11 |
Gilead Sciences Inc |
Proteinas de fusion flt3l-fc y metodos de uso.
|
|
US20220251235A1
(en)
*
|
2019-07-09 |
2022-08-11 |
Medigene Immunotherapies Gmbh |
Magea10 specific t cell receptors and their use
|
|
GB201915282D0
(en)
*
|
2019-10-22 |
2019-12-04 |
Immunocore Ltd |
Specific binding molecules
|
|
IL295023A
(en)
|
2020-02-14 |
2022-09-01 |
Jounce Therapeutics Inc |
Antibodies and fusion proteins that bind to ccr8 and their uses
|
|
CN113684258B
(zh)
*
|
2020-05-18 |
2024-08-20 |
上海赛比曼生物科技有限公司 |
用于检测鼠源tcr转基因拷贝数的试剂盒及方法
|
|
CN116322750A
(zh)
*
|
2020-06-25 |
2023-06-23 |
卫理公会医院 |
抗原特异性t细胞受体和嵌合抗原受体以及用于癌症免疫疗法的免疫信号传导调节中的使用方法
|
|
IL276599A
(en)
*
|
2020-08-09 |
2022-03-01 |
Yeda Res & Dev |
T cell receptor unique to mage-a1 and its uses
|
|
TW202406932A
(zh)
|
2020-10-22 |
2024-02-16 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
CN112279908B
(zh)
*
|
2020-10-23 |
2024-03-19 |
魏放 |
识别ebv抗原短肽的t细胞受体及其应用
|
|
TW202313094A
(zh)
|
2021-05-18 |
2023-04-01 |
美商基利科學股份有限公司 |
使用FLT3L—Fc融合蛋白之方法
|
|
JP2024539252A
(ja)
|
2021-10-28 |
2024-10-28 |
ギリアード サイエンシーズ, インコーポレイテッド |
ピリジジン-3(2h)-オン誘導体
|
|
CA3235986A1
(en)
|
2021-10-29 |
2023-05-04 |
Gilead Science, Inc. |
Cd73 compounds
|
|
US20230310607A1
(en)
|
2021-11-09 |
2023-10-05 |
T-Knife Gmbh |
Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits
|
|
EP4452414A2
(en)
|
2021-12-22 |
2024-10-30 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
EP4667056A1
(en)
|
2021-12-22 |
2025-12-24 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Parp7抑制劑
|
|
LT4245756T
(lt)
|
2022-03-17 |
2024-11-25 |
Gilead Sciences, Inc. |
Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas
|
|
US20230374036A1
(en)
|
2022-04-21 |
2023-11-23 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
CN116063458A
(zh)
*
|
2022-04-27 |
2023-05-05 |
恒瑞源正(广州)生物科技有限公司 |
Mage-a1特异性t细胞受体及其用途
|
|
IL317958A
(en)
|
2022-07-01 |
2025-02-01 |
Gilead Sciences Inc |
CD73 compounds
|
|
TW202417476A
(zh)
|
2022-08-18 |
2024-05-01 |
英商英美偌科有限公司 |
T細胞受體及其融合蛋白
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
EP4695260A1
(en)
|
2023-04-11 |
2026-02-18 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20250175331A
(ko)
|
2023-04-21 |
2025-12-16 |
길리애드 사이언시즈, 인코포레이티드 |
Prmt5 억제제 및 이의 용도
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024300557A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025027088A1
(en)
|
2023-07-31 |
2025-02-06 |
T-Knife Gmbh |
An enhanced chimeric human cd8 co-receptor, a nucleic acid encoding the enhanced chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease
|
|
WO2025027087A1
(en)
|
2023-07-31 |
2025-02-06 |
T-Knife Gmbh |
A chimeric human cd8 co-receptor, a nucleic acid encoding the chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease
|
|
WO2025045752A1
(en)
|
2023-08-25 |
2025-03-06 |
T-Knife Gmbh |
Chimeric human cd 95 switch receptor, t-cell expressing said receptor together with an engineered t-cell receptor, respective vectors, kits, pharmaceutical compositions and methods for treating a patient having a disease
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025096983A1
(en)
*
|
2023-11-02 |
2025-05-08 |
Board Of Regents, The University Of Texas System |
Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025146286A1
(en)
|
2024-01-04 |
2025-07-10 |
Immunoscape Pte. Ltd. |
Human t cell receptors and uses thereof
|
|
WO2025191067A1
(en)
|
2024-03-13 |
2025-09-18 |
T-Knife Gmbh |
A chimeric transmembrane receptor comprising at least one t-cell immunoreceptor with ig and itim domains (tigit) polypeptide region, t-cells expressing the chimeric human tigit switch receptor, vectors with nucleic acids encoding for the tigit receptor, kits for preparing the t-cells, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease and for increasing cytotoxicity of a t-cell in adoptive cell therapy
|
|
WO2025190565A1
(en)
|
2024-03-13 |
2025-09-18 |
T-Knife Gmbh |
A chimeric programmed cell death protein 1 receptor
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|